Trans-5-Chloro-2,3,3A,12B-Tetrahydro-2-Methyl-1H-Dibenz[2,3:6,7]Oxepino[4,5-C]Pyrrole Maleate

The utility of Trans-5-Chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole maleate—hereafter referred to as the Compound—resides entirely within its stereochemical architecture. The (3aR,12bS) or equivalent trans-configuration of the tetracyclic core supplies the precise geometry required for dopamine D₂ and serotonin 5-HT₂A receptor antagonism in the final benzisoxazole-piperidinyl drug substance. Commercial sourcing of the maleate salt, rather than the free base, addresses a critical production bottleneck: the maleate delivers a crystalline, non-hygroscopic solid with a melting point exceeding 195°C (decomposition), enabling ambient-temperature warehouse storage in polyethylene-lined fibre drums without the cold-chain logistics that the amorphous free base demands. Reprocessing a failed batch of free base into this salt remains the standard corrective action in multi-tonne manufacturing campaigns.

When the Compound Is Deployed in Risperidone API Manufacturing via the Chloroethylation Pathway

In GMP synthesis of risperidone, the Compound functions as the fused-ring electrophilic partner that couples with 6-fluoro-3-(4-piperidinyl)-1,2-benzisoxazole hydrochloride. The maleate salt must undergo a quantitative in-situ freebasing step immediately prior to alkylation; typical practice involves stirring the salt in a biphasic mixture of toluene and 10% aqueous sodium carbonate at 20–25°C for 45–60 minutes until complete dissolution of the solid phase is observed. The toluene layer, now carrying the free amine, is separated and azeotropically dried to a Karl Fischer endpoint below 200 ppm water. Residual moisture above 500 ppm in this stream has been repeatedly correlated with the formation of a dimeric quaternary ammonium impurity exceeding 0.15% area-by-HPLC in the crude API, a level that cannot be purged by the standard isopropanol recrystallization and will cause a batch rejection under the USP monograph limits. The alkylation itself is conducted in acetonitrile with 1.05–1.10 molar equivalents of the bisazoxide hydrochloride, catalyzed by potassium carbonate milled to a particle size distribution of D90 < 50 µm, at reflux for 16–24 hours. Inadequate carbonate fineness extends reaction time beyond 30 hours and produces an oxidized degradant with a relative retention time of 1.32 against risperidone that co-crystallizes with the product. The terminal API, following charcoal treatment and recrystallization, must exhibit a trans-isomer content exceeding 99.5% as measured by the chiral HPLC method specified in Ph. Eur. monograph 01/2023:1938.

Process Control Parameters That Determine Optical Purity Retention Across the Coupling Sequence

The trans-configuration embedded in the Compound’s 3a-12b ring junction is thermodynamically metastable; prolonged exposure to alkaline conditions at elevated temperature drives epimerization toward the cis-diastereomer. A process-scale investigation across three 2,000-litre glass-lined reactors documented that when the freebasing step is held for longer than 90 minutes at a pH exceeding 12.5, the trans-to-cis isomer ratio degrades from an initial 99.8:0.2 to 97.6:2.4—an irreversible loss that translates to a 1.9% reduction in theoretical yield across the downstream alkylation and recrystallization sequence. Operating protocols therefore cap the freebase hold time at 60 minutes and maintain the aqueous phase pH between 10.5 and 11.5 through controlled carbonate addition rates monitored by an in-situ probe. The coupling reaction temperature itself constitutes a second critical node: running the acetonitrile reflux above 82°C accelerates ring-junction scrambling even in the absence of aqueous base. Facilities employing pressurized reflux to push temperature beyond 85°C for throughput reasons report cumulative isomeric impurity loads of 0.8–1.2% in the isolated crude, requiring an additional hot-filtration step through activated carbon-impregnated cellulose pads to bring the specification below 0.3%.

Why This Maleate Intermediate Enters the Paliperidone Synthetic Route Without Decoupled Salt-Breaking

Paliperidone, the 9-hydroxy metabolite of risperidone, is commercially manufactured via two convergent strategies. The route that bypasses risperidone as an isolated intermediate—preferred because it avoids a separate regulatory filing for the risperidone step—utilizes the same maleate salt with a benzisoxazole-piperidine partner that already carries the 9-hydroxy substituent as a protected acetate ester or silyl ether. When the coupling is executed in dimethylformamide at 85–90°C with triethylamine as the acid scavenger, the maleic acid counterion need not be neutralized in a separate vessel; triethylamine itself abstracts the maleic acid proton in situ, generating triethylammonium maleate that remains soluble in the DMF mother liquor after product precipitation. The molar ratio of triethylamine to maleate salt is fixed at 2.05–2.10:1—the excess 0.05–0.10 equivalent buffers the system against trace HCl introduced with the piperidine hydrochloride coupling partner. This one-pot telescoped protocol eliminates the aqueous workup that generates 400–600 litres of toluene-contaminated wastewater per 100-kilogram batch of risperidone-route intermediate. The final paliperidone must satisfy the enantiomeric purity criterion of Ph. Eur. monograph 01/2023:2420, with the trans-enantiomer comprising not less than 99.0%.

In the formulation of long-acting injectable paliperidone palmitate suspensions, the particle size of the milled API must fall within a D50 range of 0.8–1.2 µm and D90 below 3.0 µm. Starting material sourced from Compound batches that contain residual palladium above 5 ppm—a carryover from a pyridine-ring hydrogenation step earlier in the synthesis—exhibits accelerated Ostwald ripening in aqueous suspension media buffered at pH 7.2, with the mean particle diameter increasing by 40–60% over 12 weeks at 40°C/75% relative humidity. Supplier qualification agreements for Compound intended for this downstream application routinely cap the palladium specification at <2 ppm measured by ICP-MS per USP <233>.

A distinct utilization pathway involves the preparation of pharmacopoeial impurity reference standards. The cis-epimer of risperidone, designated as Risperidone Related Compound F in USP R098U0, is synthesized from a deliberately epimerized batch of the Compound that has been subjected to pH 13.0 at 60°C for 8 hours. The resulting cis-enriched free base is then carried through the same coupling sequence. After semi-preparative chiral HPLC on a Chiralpak IA column with n-hexane:ethanol:diethylamine (80:20:0.1) mobile phase, the isolated impurity standard exhibits a chemical purity above 98.0% and is used to spike system suitability solutions at 0.5% relative to risperidone. The ring-opened degradant, formed by oxidative N-demethylation of the Compound before coupling, serves as the precursor for a second process-specific impurity standard that regulatory filings under ICH Q3A(R2) typically qualify at the 0.10% reporting threshold.

A Non-API Function: Examining the Raw Material as a Ligand-Sourcing Scaffold in Dopamine Receptor Binding Assays

The tetracyclic oxepino-pyrrole nucleus of the Compound, divorced from the benzisoxazole warhead, retains measurable affinity for the dopamine D₂ receptor in its own right. Radioligand displacement assays employing [³H]-spiperone on human cloned D₂S receptors expressed in CHO-K1 membranes yield a Ki of approximately 85–120 nM for the free base, which is roughly three orders of magnitude weaker than risperidone but sufficient for the Compound to serve as a competitive assay tool compound when a partial antagonist control is required. The maleate salt is dissolved in DMSO at 10 mM stock concentration and diluted into assay buffer (Tris-HCl 50 mM, NaCl 120 mM, KCl 5 mM, MgCl₂ 2 mM, pH 7.4) immediately before each run; stocks older than 24 hours stored at 4°C show a 15–25% rightward shift in displacement curves attributed to slow oxidation at the tertiary amine center. Published data for this specific configuration confirm that the absence of the 6-fluoro-3-piperidinyl-benzisoxazole motif eliminates 5-HT₂A binding entirely (Ki > 10,000 nM), making the Compound a D₂-preferring tool that does not confound experiments with serotonergic cross-reactivity. Contract research organizations performing off-target liability panels for novel antipsychotic candidates source the Compound at >99.0% chiral purity specifically because the cis-diastereomer shows an inverted D₂/D₃ selectivity ratio that would skew structure-activity relationship interpretations.

Shipping classification of the maleate salt under USDOT and IATA dangerous goods regulations is a frequent point of audit non-conformance in air-freight supply chains. The material is not classified as environmentally hazardous (does not meet GHS acute aquatic toxicity Category 1, 2, or 3 criteria under Reg. EC 1272/2008), yet the crystalline powder’s acute oral toxicity (rat LD50, 150–300 mg/kg per OECD 423) places it in Class 6.1, Packing Group III under UN 2811 when shipped via air. Freight forwarders who erroneously declare the consignment under a non-regulated powder generic description risk customs holds at CDG and FRA hubs. Proper outer packaging consists of a UN-certified fibreboard box (4G) containing a sealed LDPE liner within an HDPE drum, with vermiculite cushioning between the primary container and the outer box.

During large-scale recrystallization of the maleate salt from isopropanol-water mixtures (85:15 v/v), the cooling rate from 70°C to 5°C directly governs crystal habit. A linear cooling ramp of 0.1°C per minute produces dense cubic crystals with a bulk density of 0.58 g/mL and a Hausner ratio of 1.18; crash cooling at 1.5°C per minute generates needle clusters with a bulk density below 0.32 g/mL that bridge in silo discharge chutes and require mechanical agitation for continuous gravimetric feeding into the alkylation reactor. The isopropanol content of the dried cake must be driven below 500 ppm by drying under vacuum (<50 mbar) at 55°C for not less than 12 hours, because residual solvent at 2000–5000 ppm suppresses the pH of the subsequent aqueous carbonate freebasing step, inducing premature salt dissociation and free amine precipitation in the piping between the make-up tank and the reactor.

Audits of Chinese and Indian Contract Manufacturing Organizations supplying this intermediate frequently uncover a specific deviation: substituting the prescribed maleic acid with a technical-grade material containing 0.5–2.0% fumaric acid as a geometric isomer impurity. Fumaric acid, being non-hygroscopic and less soluble, co-crystallizes with the maleate salt in needle-like clusters not distinguishable by visual inspection alone. However, the fumarate contamination manifests downstream as a slow-nucleating haze in the toluene freebase extract, which passes through the 0.45 µm in-line polishing filter but matures into a fine precipitate during the alkylation hold at 80°C. The precipitate, identified by ion chromatography as the fumarate salt of the bisazoxide piperidine, fouls the condenser reflux splitter in campaigns exceeding 500 kg scale and reduces heat-transfer coefficients by 30–40% after 8 hours of run time. Supplier agreements therefore mandate maleic acid excipient-grade feedstock meeting the fumaric acid specification of Ph. Eur. monograph 01/2023:0369, with confirmatory testing by the IR absorption ratio at 1680 cm⁻¹ versus 1640 cm⁻¹.